Muscle tissue engineering has been the focus of extensive research due to its potential for
numerous medical applications, including ex vivo actuator development and clinical …

Deficiency of laminin α2 chain leads to a severe form of congenital muscular dystrophy
(LAMA2-CMD), and dystrophic symptoms progress rapidly in early childhood. Currently …

Muscular dystrophies are often caused by genetic alterations in the dystrophin-dystroglycan
complex or its extracellular ligands. These structures are associated with the cell membrane …

Most Mendelian disorders, including neuromuscular disorders, display extensive clinical
heterogeneity that cannot be solely explained by primary genetic mutations. This phenotypic …

Purpose LAMA2-related muscular dystrophy (LAMA2 MD) is an autosomal recessive
inherited disease caused by LAMA2 gene mutation. The spectrum of the phenotype is …

Congenital muscular dystrophy type-1A (Lama2-CMD) and Duchenne muscular dystrophy
(DMD) result from deficiencies of laminin-α2 and dystrophin proteins, respectively. Although …

Congenital muscular dystrophy with laminin α2 chain-deficiency (LAMA2-CMD) is a severe
muscle disorder with complex underlying pathogenesis. We have previously employed …

The adhesion molecule laminin α2 chain interacts with the dystrophin-glycoprotein complex,
contributes to normal muscle function, and protects skeletal muscles from damage …

Cell signaling is determined partially by the localization and abundance of proteins.
Dystroglycan and integrin are both transmembrane receptors that connect the cytoskeleton …

A large number of human diseases are caused by chronic tissue injury with fibrosis
potentially leading to organ failure. There is a need for more effective anti-fibrotic therapies …